19.32
6.62%
1.12
Schlusskurs vom Vortag:
$18.20
Offen:
$18.17
24-Stunden-Volumen:
453.03K
Relative Volume:
1.90
Marktkapitalisierung:
$63.23M
Einnahmen:
$7.97M
Nettoeinkommen (Verlust:
$-75.74M
KGV:
-10.12
EPS:
-1.91
Netto-Cashflow:
$-85.33M
1W Leistung:
-0.28%
1M Leistung:
+166.19%
6M Leistung:
+21.57%
1J Leistung:
+19.05%
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Firmenname
Aligos Therapeutics Inc
Sektor
Branche
Telefon
(800) 466-6059
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie ALGS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
ALGS | 19.20 | 63.23M | 7.97M | -75.74M | -85.33M | -1.91 |
VRTX | 450.30 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 747.35 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.34 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
2023-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-03-23 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-01-07 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-01-06 | Herabstufung | Jefferies | Buy → Hold |
2021-09-09 | Eingeleitet | SVB Leerink | Outperform |
2021-05-17 | Fortgesetzt | Piper Sandler | Overweight |
2020-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-11-10 | Eingeleitet | JP Morgan | Overweight |
2020-11-10 | Eingeleitet | Jefferies | Buy |
2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
Aligos Therapeutics files $400M mixed securities shelf - MSN
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - The Manila Times
Aligos Reports 100% HBV Suppression Success, Strong MASH Treatment Results in Clinical Trials | ALGS Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com
ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Aligos Therapeutics Inc (ALGS) Quarterly 10-Q Report - Quartzy
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright - Defense World
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Yahoo Canada Finance
(ALGS) Technical Pivots with Risk Controls - Stock Traders Daily
Aligos Therapeutics Reports Q3 2024 Progress - TipRanks
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - The Manila Times
Aligos Reports 46% Liver Fat Reduction in MASH Trial; Q3 Loss Widens to $19.3M | ALGS Stock News - StockTitan
Aligos planning for Phase 2 trial of treatment for hepatitis B - Liver Disease News
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - The Manila Times
(ALGS) On The My Stocks Page - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4%Should You Sell? - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Increase in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Trading 4.9% HigherStill a Buy? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges By Investing.com - Investing.com South Africa
Aligos Therapeutics (NASDAQ:ALGS) Hits New 1-Year LowWhat's Next? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges - Investing.com Australia
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos TherapeuticsIt's All About Chronic Hepatitis B - RTTNews
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6.2%Should You Sell? - MarketBeat
Aligos Therapeutics appoints new VP of Business Development By Investing.com - Investing.com Australia
Aligos Therapeutics appoints new VP of Business Development - Investing.com
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):